Jonathan Birchall serves as Executive at PhaseBio Pharmaceuticals Inc, where they oversee executive responsibilities. Since joining the company, Jonathan Birchall has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on May 20, 2022 involved receiving (via award) 20,000 shares valued at $13.6K.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| May 20, 2022 | PHAS | $13.6K | Award | 20,000 | $0.68 | Discretionary |
Jonathan Birchall currently holds 20,000 shares of PhaseBio Pharmaceuticals Inc (PHAS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Jonathan Birchall has been a net neutral trader of PHAS stock. They have purchased $0 and sold $0 worth of shares.
Jonathan Birchall's most recent insider trade was on May 20, 2022, when they sold 20,000 shares at $0.68 per share.
Get notified when new Form 4 filings are submitted